List of Enanta Pharmaceuticals patents

Patents where

Current Assignee

Name

Enanta Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11339170 Spiropyrrolidine derived antiviral agents	Patent 11339170 was granted and assigned to Enanta Pharmaceuticals on May, 2022 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	11339170	May 24, 2022
‌ US Patent 11325916 Spiropyrrolidine derived antiviral agents	Patent 11325916 was granted and assigned to Enanta Pharmaceuticals on May, 2022 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	11325916	May 10, 2022
‌ US Patent 11319325 Macrocyclic spiropyrrolidine derived antiviral agents	Patent 11319325 was granted and assigned to Enanta Pharmaceuticals on May, 2022 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	11319325	May 3, 2022
‌ US Patent 10538532 Hepatitis B antiviral agents	Patent 10538532 was granted and assigned to Enanta Pharmaceuticals on January, 2020 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	10538532	January 21, 2020
‌ US Patent 11352363 Spiropyrrolidine derived antiviral agents	Patent 11352363 was granted and assigned to Enanta Pharmaceuticals on June, 2022 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	11352363	June 7, 2022
‌ US Patent 10179792 Hepatitis B antiviral agents	Patent 10179792 was granted and assigned to Enanta Pharmaceuticals on January, 2019 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	10179792	January 15, 2019
‌ US Patent 11358953 Functionalized peptides as antiviral agents	Patent 11358953 was granted and assigned to Enanta Pharmaceuticals on June, 2022 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	11358953	June 14, 2022
‌ US Patent 11384090 Spiropyrrolidine derived antiviral agents	Patent 11384090 was granted and assigned to Enanta Pharmaceuticals on July, 2022 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	11384090	July 12, 2022
‌ US Patent 10952978 Hepatitis B antiviral agents	Patent 10952978 was granted and assigned to Enanta Pharmaceuticals on March, 2021 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	10952978	March 23, 2021
‌ US Patent 10358441 Processes for the preparation of benzodiazepine derivatives	Patent 10358441 was granted and assigned to Enanta Pharmaceuticals on July, 2019 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	10358441	July 23, 2019
‌ US Patent 10934306 Hepatitis B antiviral agents	Patent 10934306 was granted and assigned to Enanta Pharmaceuticals on March, 2021 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	10934306	March 2, 2021
‌ US Patent 7582605 Phosphorus-containing hepatitis C serine protease inhibitors	Patent 7582605 was granted and assigned to Enanta Pharmaceuticals on September, 2009 by the United States Patent and Trademark Office.		Enanta Pharmaceuticals	United States Patent and Trademark Office	7582605	September 1, 2009
‌ US Patent 10428070 Hepatitis B antiviral agents	Patent 10428070 was granted and assigned to Enanta Pharmaceuticals on October, 2019 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	10428070	October 1, 2019
‌ US Patent 10398706 Heteroaryldiazepine derivatives as RSV inhibitors	Patent 10398706 was granted and assigned to Enanta Pharmaceuticals on September, 2019 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	10398706	September 3, 2019
‌ US Patent 7384921 Polymorphic forms of 6-11 bicyclic ketolide derivatives	Patent 7384921 was granted and assigned to Enanta Pharmaceuticals on June, 2008 by the United States Patent and Trademark Office.		Enanta Pharmaceuticals	United States Patent and Trademark Office	7384921	June 10, 2008
‌ US Patent 10034893 5, 6-D	Patent 10034893 was granted and assigned to Enanta Pharmaceuticals on July, 2018 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	10034893	July 31, 2018
‌ US Patent 10988458 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof	Patent 10988458 was granted and assigned to Enanta Pharmaceuticals on April, 2021 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	10988458	April 27, 2021
‌ US Patent 10179131 Hepatitis B antiviral agents	Patent 10179131 was granted and assigned to Enanta Pharmaceuticals on January, 2019 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	10179131	January 15, 2019
‌ US Patent 10189846 Hepatitis B antiviral agents	Patent 10189846 was granted and assigned to Enanta Pharmaceuticals on January, 2019 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	10189846	January 29, 2019
‌ US Patent 10253018 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof	Patent 10253018 was granted and assigned to Enanta Pharmaceuticals on April, 2019 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	10253018	April 9, 2019
‌ US Patent 10450301 Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof	Patent 10450301 was granted and assigned to Enanta Pharmaceuticals on October, 2019 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	10450301	October 22, 2019
‌ US Patent 10457703 Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof	Patent 10457703 was granted and assigned to Enanta Pharmaceuticals on October, 2019 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	10457703	October 29, 2019
‌ US Patent 11596611 Hepatitis B antiviral agents	Patent 11596611 was granted and assigned to Enanta Pharmaceuticals on March, 2023 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	11596611	March 7, 2023
‌ US Patent 11254664 Benzodiazepine derivatives as RSV inhibitors	Patent 11254664 was granted and assigned to Enanta Pharmaceuticals on February, 2022 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	11254664	February 22, 2022
‌ US Patent 11008304 Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof	Patent 11008304 was granted and assigned to Enanta Pharmaceuticals on May, 2021 by the United States Patent and Trademark Office.	Enanta Pharmaceuticals	Enanta Pharmaceuticals	United States Patent and Trademark Office	11008304	May 18, 2021

...

Results per page:

243 results

0 selected

243 results

0 selected